Becton, Dickinson and Company (NYSE:BDX) Updates FY 2026 Earnings Guidance

Becton, Dickinson and Company (NYSE:BDX) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 12.520-12.720 for the period, compared to the consensus earnings per share estimate of 12.490. The company issued revenue guidance of -.

Analyst Ratings Changes

A number of research firms have recently issued reports on BDX. Barclays began coverage on Becton, Dickinson and Company in a research report on Tuesday, February 10th. They set an “overweight” rating and a $202.00 price target on the stock. Citigroup dropped their price target on Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating on the stock in a research report on Tuesday, February 10th. Argus dropped their price target on Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating on the stock in a research report on Monday, March 23rd. The Goldman Sachs Group began coverage on Becton, Dickinson and Company in a research report on Friday, April 10th. They set a “neutral” rating and a $167.00 price target on the stock. Finally, Stifel Nicolaus dropped their price target on Becton, Dickinson and Company from $215.00 to $175.00 in a research report on Thursday. Seven equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $184.71.

Becton, Dickinson and Company Stock Down 2.6%

BDX stock traded down $4.02 during trading on Friday, reaching $149.24. 4,473,688 shares of the company traded hands, compared to its average volume of 2,846,266. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $187.35. The business has a 50 day simple moving average of $158.49 and a 200 day simple moving average of $181.08. The company has a market capitalization of $42.49 billion, a price-to-earnings ratio of 24.35, a price-to-earnings-growth ratio of 10.32 and a beta of 0.22. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.58 and a current ratio of 1.05.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The company had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.67 billion. During the same quarter last year, the company earned $3.35 earnings per share. The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, equities research analysts anticipate that Becton, Dickinson and Company will post 12.53 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be paid a $1.05 dividend. The ex-dividend date is Tuesday, June 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.8%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 68.52%.

Becton, Dickinson and Company announced that its board has approved a share repurchase plan on Tuesday, January 27th that allows the company to repurchase $10.00 million in shares. This repurchase authorization allows the medical instruments supplier to purchase up to 0% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s board believes its stock is undervalued.

Insider Buying and Selling

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 953 shares of the stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total value of $174,027.33. Following the completion of the sale, the director directly owned 36,763 shares in the company, valued at approximately $6,713,291.43. This trade represents a 2.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold 1,102 shares of company stock valued at $198,909 in the last three months. Company insiders own 0.40% of the company’s stock.

Key Stories Impacting Becton, Dickinson and Company

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: BD posted fiscal Q2 adjusted EPS of $2.90, beating estimates of $2.77, while revenue of $4.71 billion also topped expectations. The company said sales rose 5.2% year over year, helped by strength in drug-delivery devices and surgical equipment. BD Reports Second Quarter Fiscal 2026 Financial Results
• Positive Sentiment: Management raised full-year FY 2026 adjusted EPS guidance to $12.52-$12.72, above the prior outlook and slightly ahead of consensus, reinforcing confidence in the company’s earnings trajectory. Becton Dickinson raises annual profit forecast on strength in drug delivery devices
• Positive Sentiment: Evercore raised its price target on BDX to $190 from $180, and Wells Fargo lifted its target to $161 from $157, signaling improving sentiment after the earnings update. Evercore ISI Adjusts Price Target on Becton Dickinson and Company to 190 from 180
• Neutral Sentiment: BD also appointed Vitor Roque as chief financial officer, a routine leadership change that is not likely to move the stock on its own. BD Appoints Vitor Roque Chief Financial Officer
• Neutral Sentiment: Stifel cut its price target to $175 from $215, but the new target still implies upside, so the note appears more like a reset than a bearish call. Stifel Nicolaus Adjusts Becton Dickinson and Company Price Target to 175 from 215

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Imprint Wealth LLC purchased a new position in shares of Becton, Dickinson and Company in the third quarter worth about $25,000. Prosperity Bancshares Inc purchased a new position in shares of Becton, Dickinson and Company in the fourth quarter worth about $29,000. Johnson Financial Group Inc. purchased a new position in shares of Becton, Dickinson and Company in the third quarter worth about $33,000. Kelleher Financial Advisors purchased a new position in shares of Becton, Dickinson and Company in the third quarter worth about $37,000. Finally, Miller Capital Partners Inc. purchased a new position in shares of Becton, Dickinson and Company in the fourth quarter worth about $43,000. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.